创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

交泰丸调控胰腺5-羟色胺系统改善胰岛β细胞功能的机制研究

Mechanistic Study of Jiao-Tai-Wan on Improving Pancreatic Islet β Cell Function by Regulating Pancreatic 5-Hydroxytryptamine System

  • 摘要: 背景 胰岛β细胞功能损伤是2型糖尿病(type 2 diabetes mellitus,T2DM)的主要病理机制之一。胰岛β细胞自身分泌的血清素5-羟色胺(5-hydroxytryptamine,5-HT)在葡萄糖刺激下能够增加胰岛β细胞数量并促进胰岛素分泌。交泰丸(Jiao-Tai-Wan,JTW)是一种具有降糖功效的传统中药方剂。然而,JTW是否通过调控胰腺5-HT系统改善胰岛β细胞功能损伤,目前尚不明确。目的 探究JTW在db/db小鼠中的降糖作用及其具体分子机制。方法 制备JTW溶液,采用高效液相色谱法鉴定其主要活性成分。将所有db/db小鼠随机分为5组,每组8只,分别为:糖尿病模型组(Mod组,灌胃等体积蒸馏水)、二甲双胍组(Met组,灌胃剂量0.25 g ·kg-1·d-1)、交泰丸低剂量组(JTWL组,灌胃剂量2.1 g ·kg-1·d-1)、交泰丸中剂量组(JTWM组,灌胃剂量4.2 g ·kg-1·d-1)和交泰丸高剂量组(JTWH组,灌胃剂量8.4 g ·kg-1·d-1)。实验周期为6周,每周测量小鼠体重和空腹血糖(fasting plasma glucose,FPG),6周后内眦取血后脱颈处死小鼠。通过苏木素-伊红染色评估胰腺组织形态,采用酶联免疫吸附分析(enzyme-linked immunosorbent assay,ELISA)检测各组小鼠血清胰岛素表达水平,采用定量逆转录聚合酶链反应(quantitative reverse transcription polymerase chain reaction,qRT-PCR)检测胰腺组织中Ins1Ins2的信使核糖核酸(messenger RNA,mRNA)表达水平。采用ELISA、qRT-PCR、免疫荧光或免疫组化方法,评估胰腺5-HT系统相关指标的表达情况,包括5-HT、5-羟色胺受体2B(5-hydroxytryptamine receptor 2B,5-HTR2B)和瞬时受体电位锚蛋白1(transient receptor potential ankyrin 1,TRPA1)。结果 JTW可降低db/db小鼠的FPG水平,但对其体重无显著影响。同时,JTW可改善db/db小鼠的胰岛细胞形态结构,升高血清胰岛素浓度,上调胰腺组织中Ins1Ins2的mRNA表达水平。此外,JTW还可上调db/db小鼠胰腺组织中5-HT、5-HTR2B和TRPA1的表达。结论 JTW可通过调控胰腺5-HT系统改善胰岛β细胞功能,为阐明JTW治疗T2DM的具体分子机制提供了新的研究思路。

     

    Abstract: Background Impairment of pancreatic islet β cell function is one of the main pathological mechanisms of type 2 diabetes mellitus (T2DM). Serotonin (5-hydroxytryptamine, 5-HT) secreted by pancreatic islet β cells themselves can increase the number of pancreatic islet β cells and promote insulin secretion under glucose stimulation. Jiao-Tai-Wan (JTW) is a traditional Chinese medicine formula with hypoglycemic effect. However, it is currently unclear whether JTW improves impaired pancreatic islet β cell function by regulating the pancreatic 5-HT system. Objective To explore the hypoglycemic effect of JTW in db/db mice and its specific molecular mechanism. Methods JTW solution was prepared, and its main active ingredients were identified by high-performance liquid chromatography. All db/db mice were randomly divided into 5 groups with 8 mice in each, namely: diabetic model group (Mod group, intragastric administration of equal volume of distilled water), metformin group (Met group, intragastric administration at 0.25 g ·kg-1·d-1), low-dose JTW group (JTWL group, intragastric administration at 2.1 g ·kg-1·d-1), medium dose JTW group (JTWM group, intragastric administration at 4.2 g ·kg-1·d-1), and high-dose JTW group (JTWH group, intragastric administration at 8.4 g ·kg-1·d-1). The experiment lasted for 6 weeks. The body weight and fasting plasma glucose (FPG) of mice were measured weekly. After 6 weeks, blood was collected from the canthus, and the mice were sacrificed by cervical dislocation. Pancreatic tissue morphology was evaluated by hematoxylin-eosin staining. The serum insulin level was detected by enzyme-linked immunosorbent assay (ELISA). The messenger RNA (mRNA) expression levels of Ins1 and Ins2 in pancreatic tissue were detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The expression of indicators related to the pancreatic 5-HT system, including 5-HT, 5-hydroxytryptamine receptor 2B (5-HTR2B), and transient receptor potential ankyrin 1 (TRPA1) was evaluated by ELISA, qRT-PCR, immunofluorescence, or immunohistochemistry. Results JTW reduced the FPG levels of db/db mice, but had no significant effect on their body weight. Meanwhile, JTW improved the morphological structure of pancreatic islet cells, increased the serum insulin concentration, and up-regulated the mRNA expression levels of Ins1 and Ins2 in pancreatic tissue. In addition, JTW also up-regulated the expression of 5-HT, 5-HTR2B, and TRPA1 in the pancreatic tissue of db/db mice. Conclusion JTW can improve pancreatic islet β cell function by regulating the pancreatic 5-HT system, which provides a new research idea for clarifying the specific molecular mechanism of JTW in the treatment of T2DM.

     

/

返回文章
返回